What was the overall market valuation of the biologic therapy market in Germany in 2024?

The overall market valuation was $27.78 Billion in 2024. Read More

What is the projected market valuation for the biologic therapy market in Germany by 2035?

The projected valuation for 2035 is $36.5 Billion. Read More

What is the expected CAGR for the biologic therapy market in Germany during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 2.51%. Read More

Which segment of biologic therapy had the highest valuation in 2024?

In 2024, the Monoclonal Antibodies segment had the highest valuation at $10.0 Billion. Read More

What is the projected valuation for the Cell Therapy segment by 2035?

The projected valuation for the Cell Therapy segment by 2035 is $7.0 Billion. Read More

Which application area is expected to grow the most in the biologic therapy market by 2035?

The Oncology application area is expected to grow the most, reaching $11.0 Billion by 2035. Read More

What was the valuation of the Home Healthcare segment in 2024?

The Home Healthcare segment was valued at $9.78 Billion in 2024. Read More

Which key player is recognized for its leadership in the biologic therapy market in Germany?

AbbVie is recognized for its leadership in the biologic therapy market in Germany. Read More

What is the projected valuation for the Intravenous route of administration by 2035?

The projected valuation for the Intravenous route of administration by 2035 is $13.0 Billion. Read More

How does the valuation of the Autoimmune Diseases application compare to that of Cardiovascular Diseases in 2024?

In 2024, the Autoimmune Diseases application was valued at $7.0 Billion, while Cardiovascular Diseases was valued at $7.28 Billion. Read More

Germany Biologic Therapy Market

ID: MRFR/Pharma/52744-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

Germany Biologic Therapy Market Size, Growth Research Report By Therapy Type (Monoclonal Antibodies, Vaccines, Cell Therapy, Gene Therapy), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By Route of Administration (Intravenous, Subcutaneous, Intramuscular) and By End User (Hospitals, Clinics, Home Healthcare) - Competitor Industry Analysis and Trends Forecast Till 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Billion)
  1. 4.1.1 Monoclonal Antibodies
  2. 4.1.2 Vaccines
  3. 4.1.3 Cell Therapy
  4. 4.1.4 Gene Therapy
2. 4.2 Pharmaceutical, BY Application (USD Billion)
  1. 4.2.1 Oncology
  2. 4.2.2 Autoimmune Diseases
  3. 4.2.3 Infectious Diseases
  4. 4.2.4 Cardiovascular Diseases
3. 4.3 Pharmaceutical, BY Route of Administration (USD Billion)
  1. 4.3.1 Intravenous
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Intramuscular
4. 4.4 Pharmaceutical, BY End-user (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Home Healthcare
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Amgen (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Gilead Sciences (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY TYPE
3. 6.3 GERMANY MARKET ANALYSIS BY APPLICATION
4. 6.4 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 GERMANY MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Billion)
16. 6.16 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
18. 6.18 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Germany Biologic Therapy Market Segmentation

Germany Biologic Therapy Market By Type (USD Billion, 2025-2035)

Monoclonal Antibodies
Vaccines
Cell Therapy
Gene Therapy

Germany Biologic Therapy Market By Application (USD Billion, 2025-2035)

Oncology
Autoimmune Diseases
Infectious Diseases
Cardiovascular Diseases

Germany Biologic Therapy Market By Route of Administration (USD Billion, 2025-2035)

Intravenous
Subcutaneous
Intramuscular

Germany Biologic Therapy Market By End-user (USD Billion, 2025-2035)

Hospitals
Clinics
Home Healthcare

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”